Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Colorectal Cancer
Interventions
DRUG

Irinotecan

Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression

DRUG

Avastin

Avastin (IV) 10 mgr/Kgr on day 1 every 2 weeks until progression

DRUG

Erbitux

Erbitux (IV)500 mg/m2 on day 1 every two weeks until progression

Trial Locations (8)

Unknown

University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupoli

401 Military Hospital of Athens, Athens

": Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens

Air Forces Military Hospital of Athens, Athens

"IASO General Hospital of Athens, 1st Dep of Medical Oncology", Athens

State General Hospital of Larissa, Larissa

"Metaxa's Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology", Piraeus

"Theagenion Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology", Thessaloniki

All Listed Sponsors
collaborator

University Hospital of Crete

OTHER

lead

Hellenic Oncology Research Group

OTHER